北米の免疫抑制薬市場予測2019-2028

◆英語タイトル:NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET FORECAST 2019-2028
◆商品コード:INK20AG085
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2020年1月
◆ページ数:105
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:北米
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥131,250見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥157,500見積依頼/購入/質問フォーム
Enterprisewide PriceUSD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

KEY FINDINGSThe North America immunosuppressant drugs market is projected to record growth at a CAGR of 3.19% during the forecast period, 2019-2028. The surge in demand for organ transplantation, as a result of increasing organ failure incidences, is the influential factor in stimulating market growth.

MARKET INSIGHTS
The North America immunosuppressant drugs market growth analysis involves market evaluation of Canada and the United States. Canada has the presence of major pharmaceutical companies. The pharmaceutical industry of the country comprises of an ecosystem of local and multinational companies. A large part of the Canadian population is affected by autoimmune diseases. Sjögren’s syndrome is one such autoimmune disorder that is prevalent in Canada. Immunosuppressant drugs are an instrumental part of treatment for such autoimmune disorders. Over the years, there has been an increase in the NDD (NDD, or neurological determination of death) donors and a decrease in the DCD (donation after cardio-circulatory death) donors. DCD was practiced in the country since 2006. There have also been significant variations in the type of organs being transplanted. Such factors are attributed to the growth of the market under study.

COMPETITIVE INSIGHTS
Some of the eminent companies progressing in the market are Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Astellas Pharma Inc, AbbVie Inc, Cipla Ltd, etc.

Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

【レポートの目次】

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. DEVELOPMENT OF IMMUNOSUPPRESSANT DRUGS
3.2. MARKET DEFINITION
3.3. KEY DRIVERS
3.3.1. INCREASE IN THE NUMBER OF AUTOIMMUNE DISORDERS
3.3.2. RISE IN ORGAN TRANSPLANTATION
3.3.3. GROWTH IN THE PHARMACEUTICAL INDUSTRY
3.4. KEY RESTRAINTS
3.4.1. SIDE EFFECTS OF IMMUNOSUPPRESSANT DRUGS
3.4.2. LACK OF AWARENESS ABOUT ORGAN DONATION
4. KEY ANALYTICS
4.1. KEY INVESTMENT INSIGHTS
4.2. PORTER’S FIVE FORCE ANALYSIS
4.2.1. BUYER POWER
4.2.2. SUPPLIER POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. OPPORTUNITY MATRIX
4.4. VENDOR LANDSCAPE
5. MARKET BY DISTRIBUTION CHANNEL
5.1. HOSPITAL PHARMACIES
5.2. RETAIL PHARMACIES
5.3. ONLINE PHARMACIES
6. MARKET BY END-USER
6.1. ORGAN TRANSPLANTATION
6.2. AUTOIMMUNE DISORDERS
6.3. OTHERS
7. MARKET BY DRUG CLASS
7.1. CORTICOSTEROIDS
7.2. MONOCLONAL ANTIBODIES
7.3. CALCINEURIN INHIBITORS
7.4. MTOR INHIBITORS
7.5. OTHERS
8. GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1. UNITED STATES
8.1.2. CANADA
9. COMPANY PROFILES
9.1. ABBVIE INC
9.2. ALLERGAN PLC (ACQUIRED BY ABVIE INC)
9.3. ASTELLAS PHARMA INC
9.4. BRISTOL-MYERS SQUIBB COMPANY
9.5. CIPLA LTD
9.6. DR. REDDY’S LABORATORIES LTD
9.7. F HOFFMANN-LA ROCHE AG
9.8. GLAXOSMITHKLINE PLC
9.9. INTAS PHARMACEUTICALS LTD (ACCORD HEALTHCARE LTD)
9.10. JANSSEN PHARMACEUTICALS NV (JHONSON & JHONSON)
9.11. MYLAN NV
9.12. NOVARTIS INTERNATIONAL AG (SANDOZ)
9.13. PFIZER INC
9.14. SANOFI SA
9.15. VELOXIS PHARMACEUTICALS

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT - IMMUNOSUPPRESSANT DRUGS
TABLE 2: SIDE EFFECTS OF IMMUNOSUPPRESSANT DRUGS
TABLE 3: TOP 15 POSITIVE NET EXPORTS COUNTRIES AND NEGATIVE NET EXPORTS FOR DRUGS & MEDICINES COUNTRIES
TABLE 4: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 5: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 6: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 7: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 8: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 9: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY CLASS, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 10: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 11: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)


【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[北米の免疫抑制薬市場予測2019-2028]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆